Singulex, Inc. Announces Two Studies Utilizing Company’s Proprietary System For Cardiovascular Risk Assessment At American Heart Association Scientific Sessions

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced two studies using the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI) will be presented at the American Heart Association Scientific Sessions in Dallas, Texas.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC